ZA968444B - Methods of inhibiting plasminogen activator inhibitor 1. - Google Patents

Methods of inhibiting plasminogen activator inhibitor 1.

Info

Publication number
ZA968444B
ZA968444B ZA9608444A ZA968444A ZA968444B ZA 968444 B ZA968444 B ZA 968444B ZA 9608444 A ZA9608444 A ZA 9608444A ZA 968444 A ZA968444 A ZA 968444A ZA 968444 B ZA968444 B ZA 968444B
Authority
ZA
South Africa
Prior art keywords
methods
plasminogen activator
activator inhibitor
inhibiting plasminogen
inhibiting
Prior art date
Application number
ZA9608444A
Other languages
English (en)
Inventor
David Thompson Berg
Brian William Grinnell
Mark Alan Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA968444B publication Critical patent/ZA968444B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA9608444A 1995-10-10 1996-10-07 Methods of inhibiting plasminogen activator inhibitor 1. ZA968444B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US501595P 1995-10-10 1995-10-10

Publications (1)

Publication Number Publication Date
ZA968444B true ZA968444B (en) 1998-04-07

Family

ID=21713702

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9608444A ZA968444B (en) 1995-10-10 1996-10-07 Methods of inhibiting plasminogen activator inhibitor 1.

Country Status (20)

Country Link
US (1) US5731328A (es)
EP (1) EP0854715B1 (es)
JP (1) JPH11513665A (es)
KR (1) KR19990064099A (es)
CN (1) CN1199337A (es)
AR (1) AR003812A1 (es)
AT (1) ATE255414T1 (es)
AU (1) AU716655B2 (es)
CA (1) CA2234404A1 (es)
CO (1) CO4750819A1 (es)
CZ (1) CZ106098A3 (es)
DE (1) DE69630969T2 (es)
EA (1) EA001003B1 (es)
ES (1) ES2211981T3 (es)
HU (1) HUP9802348A3 (es)
NO (1) NO981578L (es)
NZ (1) NZ319948A (es)
PL (1) PL326294A1 (es)
WO (1) WO1997013511A1 (es)
ZA (1) ZA968444B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2006088011A1 (ja) * 2005-02-15 2006-08-24 Tokai University Educational System プラスミノーゲンアクチベーターインヒビター－１阻害剤
EP1942930A2 (en) * 2005-10-11 2008-07-16 Amano Enzyme USA., Ltd. Enzyme inhibitors of pai-1
CN101544138B (zh) * 2008-03-26 2012-05-23 山东新北洋信息技术股份有限公司 热转印打印机碳带回收装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
ATE260104T1 (de) * 1993-12-21 2004-03-15 Lilly Co Eli Hemmung der endprodukte fortgeschrittener glykolisierung

Also Published As

Publication number Publication date
NZ319948A (en) 2000-06-23
AU7259696A (en) 1997-04-30
ES2211981T3 (es) 2004-07-16
CO4750819A1 (es) 1999-03-31
ATE255414T1 (de) 2003-12-15
CA2234404A1 (en) 1997-04-17
CZ106098A3 (cs) 1999-03-17
US5731328A (en) 1998-03-24
HUP9802348A3 (en) 1999-11-29
NO981578D0 (no) 1998-04-07
HUP9802348A2 (hu) 1999-08-30
EA199800366A1 (ru) 1998-10-29
WO1997013511A1 (en) 1997-04-17
AU716655B2 (en) 2000-03-02
KR19990064099A (ko) 1999-07-26
EP0854715A4 (en) 2001-12-19
JPH11513665A (ja) 1999-11-24
EP0854715B1 (en) 2003-12-03
EA001003B1 (ru) 2000-08-28
CN1199337A (zh) 1998-11-18
AR003812A1 (es) 1998-09-09
DE69630969T2 (de) 2004-10-21
PL326294A1 (en) 1998-09-14
NO981578L (no) 1998-04-07
DE69630969D1 (de) 2004-01-15
EP0854715A1 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
PL327569A1 (en) Promedications of thrombosin inhibitors
PL323710A1 (en) Reversible inhibitors of cysteinic protease
PL314838A1 (en) Inhibitors of bp-iv-serine protease
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PL326508A1 (en) Protease inhibitors
EP0693083A4 (en) ALPHACETOAMIDE DERIVATIVES USEFUL AS THROMBOSIS INHIBITORS
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
PL321759A1 (en) Novel thrombosin inhibitors
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
IL108075A0 (en) Enzyme inhibitors
IL118101A0 (en) Inhibitors of farnesyltransferase
EP0820453A4 (en) THROMBIN INHIBITORS
AU1515295A (en) Inhibitors of urokinase plasminogen activator
IL123268A0 (en) PEP inhibitor
AU7431796A (en) Brain-associated inhibitor of tissue-type plasminogen activator
ZA968444B (en) Methods of inhibiting plasminogen activator inhibitor 1.
ZA964682B (en) Methods of inhibiting melanoma.
GB9502985D0 (en) Enzyme inhibitors
EP0713496A4 (en) THROMBINE INHIBITORS TARGETED ON FIBRIN
ZA934970B (en) Enzyme inhibitors
AU7357996A (en) Pancreas-derived plasminogen activator inhibitor
ZA9610763B (en) Low rate application of inhibitors of ethylene biosynthesis or action.
ZA939480B (en) Enzyme inhibitor
GB9405905D0 (en) Inhibitors of isoprenylated protein endoprotease